Dutch language

How to pronounce subgroup in Dutch?

Full Transcript

so today I'm going to present to you the
post hoc analysis of a study which we
try to look at the response and also in
terms of the advocacy and safety of out
rumblepack treatment in patients with
persistent versus chronic ITP patients
now first of all as you all know immune
from lazada pinna or ITP is an
autoimmune disease resulting in the in
from post a leukemia and currently the
disease is classified in two different
phases okay according to the time from
diagnosis so within the first three
months of diagnosis is usually called
newly diagnosed ITP and from three
months to twelve months is called
persistent ITP and patients with the
diagnosis of more than 12 months are
usually called from the ITP we don't in
the bone marrow did form a point in
actually stimulating megakaryocyte to
produce playlet and in a number of
clinical trials we have already
demonstrated that from avoiding receptor
agonists can actually improve the plate
account in patients with immune from the
south of India and then rumble Pak is
one of the four important receptor
agonists which is currently available in
the market it has me to prove to the
urge to be used in patients with chronic
IDP who has already failed other forms
of treatment for example corduroy or
IVIG or any other treatment so so far we
only have we have very few analysis we
try to actually look into the issue
whether the drug is actually effective
or safe in patients with persistent ITP
and means patients who have been
diagnosed with ITP three months to 12
months so in this study in this analysis
we're trying to present you the data
from a face for open label study in
international trial which initially
we've conducted to evaluate the in fact
of eltrombopag on the bone marrow
fibrosis so as you can see here this
summarize the design of the study so
basically we have recruited patients
with ITP and we mainly exclude patients
who have actually got recently treated
with formal quality receptor agonist
within the past six month and also we
exclude the patients with severe
myelofibrosis that means MF grade 3 okay
according to the European consensus
grading system okay and these patients
will then be treated without rumblepack
for to the duration of two years okay as
you can see here in this line okay you
can see a few figures in circle and
basically the summarize the dosage of
eltrombopag that we used and basically
the starting dose of our combo pack was
15 milligram in most patients except
those patients who are East Asian
ancestry because they usually have a
high exposure to the drug so we start
with 25 milligram per day and then the
in all patients the dose allowed to
titrate to a maximum of 75 milligram per
day and we did perform the bone marrow
examination and screening before
treatment one year and two years after
treatment to evaluate any change in the
fibrosis of the marrow as you can see
here in this study we recruited patients
who have got the ITP diagnosis for six
months or more so we do including
increase some patients who are in the
interface of persistent ITP so this is a
business line okay we summarized the
baseline characteristics of the patients
that we recruited we've recruited a
total of 162 patients as you can see
here close to one quarter of these
patients actually had persistent ITP
and about 3/4 of the patients has got it
from the ITP now I don't want to go into
excepted detail one by one category by
one category but I can I can share with
you that in terms of the sex the age are
the playlet Khong and the prior use of
formal party receptor agonists the two
groups are actually quite similar in
terms of the baseline characteristics
although this is not exactly a
randomized controlled study and we don't
do it we don't do it actually by purpose
the only difference we can see between
the two groups are their number of
patients who have got spin that can be
done and this is quite expected because
in clinical practice we don't usually
usually recommend spin ectomy in the
a bit later so looking at the overall
conduction of his study as you can see
here most of the patient had she
completed the study but of course we do
have some patient who withdrew earlier
because either of the lack of efficacy
or Everest event as summarize in this
figure in terms of the duration of
exposure and the dose of our trauma pact
that we use you can see that here we we
summarize the data on the persistent ITP
group and it from the ITP group and
basically you see very similar result
both in terms of the median dose of the
drug that we use and also the duration
of exposure this line actually summarize
the player response that we see in this
study okay as you can see here basically
if we take say using played account at
least 50 times 10 to a power 9 per liter
that's kind of a safe value which many
of us use it okay to guide our treatment
you can see that without any rescue
therapy this level of play account was
achieved in more than 80 percent of the
patients in the study
it was achieved in about 84% of the
patient would persist in ITP and also in
about 88% of the patients with from the
ITP in the figure okay you can see that
we try to summarize the median play the
count throughout the two years study
period and you can see here the blue
line is the patients with persistent ITP
and the orange line so patients with
chronic ITP we see that the two lights
actually overlap with each other very
well
indicating that the media in terms of
the planet responds to two groups of
patients show exactly the same kind of
results let's look at the plate respond
in a little bit more detail okay how
quickly did it occur now this line
actually summarized median time to
achieve a play count of at least 50
times 10 to power 9 per liter as you can
see here they're actually in both group
the respond occur pretty quickly it
takes a median about four weeks for the
position ITP patients to achieve this
safe play account and about an median of
are on two weeks for the patients with
Chrome the idea
to achieve this I play that cow how
about the sustainability is the response
sustained the answer is yes as you can
see here if you look at the game we've
summarized here the blue bars a
persistent ITP the orange bar is the
chronic ITP patients we see roughly
about 2/3 of the patient has got a
sustained response without any rescue
therapy for more than 28 weeks at least
and you can see that you continue to
follow this patient they certainly need
some patients who can actually achieve a
sustained play the response for even a
lot for even longer and you see you
don't see any difference in terms of
proportion of the patients between the
persistent versus the chronic ITP
subgroup of patients about 40% of the
patients in both subgroup the the
developer will lapse of the of the ITP
and require some for fast rescue
treatment and most of this patient has
yes treated here receive another new ITV
medications this lie is a business lie
and the one I didn't want to go through
line by line but this summarize the
adverse event the safety profile
including the serious adverse event
summary again we receive very similar
safety profile in terms of adverse event
between the patients with persistent
versus chronic ITP except a few which
have highlighted here we say there'll be
more patients in the persistent ITP
groups of patients with pain some join
paying some vertigo and also some
dyspepsia but we believe that this
difference may be is explained actually
explained but a very limited number of
patients that we have in the persistent
ITP group with smaller denominator we
certainly see you know sometimes a
little bit sort of actuation in the
results this study among the 37 patients
on the left-hand side okay with
persistent ITP none of the patients died
throughout the study period for the
chronic ITP patients three patients died
out of the 124 patients included -
unfortunately died of cerebral
Hammond's cranial hemorrhage again this
is actually an important cause of
mortality in patients with ITP there was
another patient who died of a Cuba's
protrude distress syndrome but none of
these event were actually considered
relate to the drum so we believe that
the drug was actually equally safe in
these two groups of patients as I've
mentioned initially the primary aim of
the study was actually to look at the
bone marrow fibrosis that may be related
to the out rumble pack in this study as
summarized here again on the left hand
side so patient persistent ITP in the
right hand size included patients with
chronic ITP you can see that majority
vast majority of patients they don't
show any significant change in terms of
the fibrosis in the bone marrow okay so
basically the primary analysis of this
of this study was which was published
last year in the annals of hematology we
have already concluded that the use of a
chronopath is not associated with any
clinically significant fibrosis in the
bone marrow and again we don't see any
difference between these two subgroup of
patients
so in summary ladies and gentlemen in
this study after is post hoc analysis I
think we have shown that basically the
advocacy and the safety following out
rumblepack treatment as are actually
consistent between those patient with
persistent ITP which is those patients
with chronic ITP and the results in both
Sarabhai actually quite encouraging so
based on the data I think we can
conclude that even if we use the drug
earlier we certainly will give the same
level of efficacy and safety so before I
finish my presentation I would like to
thank the sponsor of this study
Novartis we should also provide some
support in making these lies that way
but I will also like to thank all the
investigators and the patients for the
participation in this study without them
we certainly would not have the results
in this post hoc analysis thank you very
much for attention I'm happy to take
your comment any questions
[Applause]

so today I'm going to present to you the

Toggle Transcript

subgroup::noun | Spocien Dictionary

subgroup

noun

/'səb,grup/

a distinct and often subordinate group within a group

Type	Words
Type of	grouping, group
Has types	bench

subgroup::noun | Spocien Dictionary

subgroup

noun

/'səb,grup/

(mathematics) a subset (that is not empty) of a mathematical group

Type	Words
Type of	group, mathematical group

How to pronounce subgroup in Dutch?

subgroup::noun | Spocien Dictionary

abandonment

Related words

subgroup::noun | Spocien Dictionary

abandonment

Related words

Related

Subscribe to our Newslatter